Blocking and randomization to improve molecular biomarker discovery.
Randomization and blocking have the potential to prevent the negative impacts of nonbiologic effects on molecular biomarker discovery. Their use in practice, however, has been scarce. To demonstrate the logistic feasibility and scientific benefits of randomization and blocking, we conducted a microRNA study of endometrial tumors (n = 96) and ovarian tumors (n = 96) using a blocked randomization design to control for nonbiologic effects; we profiled the same set of tumors for a second time using no blocking or randomization. We assessed empirical evidence of differential expression in the two studies. We performed simulations through virtual rehybridizations to further evaluate the effects of blocking and randomization. There was moderate and asymmetric differential expression (351/3,523, 10%) between endometrial and ovarian tumors in the randomized dataset. Nonbiologic effects were observed in the nonrandomized dataset, and 1,934 markers (55%) were called differentially expressed. Among them, 185 were deemed differentially expressed (185/351, 53%) and 1,749 not differentially expressed (1,749/3,172, 55%) in the randomized dataset. In simulations, when randomization was applied to all samples at once or within batches of samples balanced in tumor groups, blocking improved the true-positive rate from 0.95 to 0.97 and the false-positive rate from 0.02 to 0.002; when sample batches were unbalanced, randomization was associated with the true-positive rate (0.92) and the false-positive rate (0.10) regardless of blocking. Normalization improved the detection of true-positive markers but still retained sizeable false-positive markers. Randomization and blocking should be used in practice to more fully reap the benefits of genomics technologies.
Authors' Affiliations: Departments of Epidemiology and Biostatistics and qinl@mskcc.org.
Li-Xuan
LX
Qin
Authors' Affiliations: Departments of Epidemiology and Biostatistics and.
Qin
Q
Zhou
Surgery, and.
Faina
F
Bogomolniy
Genomics Core Laboratory, Memorial Sloan-Kettering Cancer Center, New York, New York.
Liliana
L
Villafania
Surgery, and.
Narciso
N
Olvera
Genomics Core Laboratory, Memorial Sloan-Kettering Cancer Center, New York, New York.
Magali
M
Cavatore
Authors' Affiliations: Departments of Epidemiology and Biostatistics and.
Jaya M
JM
Satagopan
Authors' Affiliations: Departments of Epidemiology and Biostatistics and.
Colin B
CB
Begg
Surgery, and.
Douglas A
DA
Levine
D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D003198:Computer Simulation; D057225:Data Mining; D016889:Endometrial Neoplasms / Q000235:genetics / Q000473:pathology; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000235:genetics; D015233:Models, Statistical; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology; D011897:Random Allocation; D012107:Research Design / Q000592:standards*
D014408:Biomarkers, Tumor; D035683:MicroRNAs